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A simple and rapid UPLC/MS/MS method has been developed and validated for the analysis of digoxin and metildigoxin in whole
blood. Samples were prepared by SPE extraction with Oasis HLB columns. Separation was achieved with an ACQUITY UPLC
HSS T3 column (2.1 × 100; 1.8μm), at 35◦C. The mobile phase consisted of acetonitrile (70%) and ammonium formate 5mM
(30%). Total run time was 1.5min operating at isocratic mode with a ﬂow rate of 0.3mL/min. Mass spectrometry detection was
performed by positive mode electrospray, on the ammonium adducts with two transitions for each analyte and one for the IS (d3-
digoxin). The method proved to be speciﬁc and linear over the range (0.3–10)ng/mL. This technique also showed high sensitivity
with a 0.09ng/mL LOD and a 0.28ng/mL LOQ, for both substances. Percentage recovery ranged from 83 to 100% for digoxin and
from 62 to 94% for metildigoxin. The intra- and interday precision CV were ≤10%.
1.Introduction
Digitalis glycosides are the drugs of choice for the treatment
ofcongestiveheartfailureandcertaindisturbancesincardiac
rhythm, producing a positive inotropic activity and increase,
myocardial contractility [1]. Some authors state that digoxin
is clinically the most commonly used cardiac glycoside [2].
Nevertheless, in Portugal, metildigoxin is also a common
cardiac glycoside, being the second more frequently used [3].
Digoxin (Figure 1) is metabolised mainly in the liver [2], by
stepwise removal of the sugar moieties to form digoxigenin,
which is further metabolised to inactive metabolites which
may be excreted in free or conjugated forms. Reduction to
dihydrodigoxin, relatively inactive, also occurs [4]. However,
digoxin is metabolised in man in a small percentage [5].
Eﬀectively, digoxin is excreted mainly unaltered in the urine,
with up to 80% of a dose excreted in urine in 7 days being
27% of the dose excreted in the ﬁrst 24h [4]. Digoxin can be
foundastheresultofitsadministrationorduetometabolism
since it is a metabolite of deslanoside, digitoxin, lanatoside C
and metildigoxin [4]. Metildigoxin (Figure 2)i sm e t a b o l i z e d
by demethylation into digoxin and by hydrolysis into the
bis- and monoglycosides. About 75% of a dose is excreted in
urineoveraseveraldaysperiod,withabout25–30%excreted
in the ﬁrst 24h. About 30–50% of the material excreted in
urinecorrespondstounchangeddrug,being15%conjugated
bis- and monoglycosides and the remains are digoxin [4].
These compounds have a narrow therapeutic range, so
they can frequently lead to intoxication, involving suicide,
homicide, and accidental poisoning cases [2]. When this
intoxicationislethal,legalproceduresareimplicated,andthe
forensic laboratories must conﬁrm the existence of cardiac
glycosides in the collected samples to help determine if digi-
talis intoxication was, in fact, the causeof death. Therefore, it
is essential that toxicology laboratories are capable to detect
andquantifythisgroupofsubstancesinpostmortemsamples.2 International Journal of Analytical Chemistry
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Figure 1: Chemical structure of digoxin (C41H64O14).
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Figure 2: Chemical structure of metildigoxin (C42H66O14).
In this study, we have developed a sensitive and rapid
method for the identiﬁcation and quantiﬁcation of digoxin
and metildigoxin in whole blood by UPLC-MS/MS, after
a SPE extraction technique.
2. Experimental
2.1. Instrumentation. Chromatographic separation was car-
ried out on an ACQUITY UPLC system (Waters) with an
ACQUITYTQDMassDetector(Waters).Solid-phaseextrac-
tions were carried out on an automatic extractor Aspec XL
(Gilson).
2.2. Materials, Standards, and Chemicals. Pure digoxin,
metildigoxin, and d3-digoxin (internal standard) were pur-
chased from Chemos (Germany). Each standard com-
pound was dissolved in methanol (1mg/mL for digoxin
and 0.5mg/mL for metildigoxin and d3-digoxin) and
stored at −20◦C. Working solutions were also prepared in
methanol. Ammonium formate was purchased from Sigma-
Aldrich (USA). Ammonium acetate was purchased from
Merck (Darmstadt, Germany). All the other solvents were
analytical or HPLC grade and were purchased from E. Merck
(Darmstadt, Germany). Water was puriﬁed by a Milli-Q
system obtained from Millipore (Molsheim, France). The
mobilephasewasﬁlteredwitha0.20μmSchleicher&Schuell
ﬁlter and degassed in an ultrasonic bath for 15 minutes just
before use. Oasis HLB (3cc; 60mg) solid-phase extraction
columns were obtained from Waters (Via Athena, Portugal).
2.3.UPLC-MS/MSConditions. Chromatographicseparation
was performed with an ACQUITY UPLC HSS T3 column
(2.1 × 100; 1.8μmp a r t i c l es i z e ) ,a t3 5 ◦C. The mobile
phase consisted of acetonitrile (70%) and ammonium for-
mate 5mM (30%). Total run time was 1.5min operating
at isocratic mode with a ﬂow rate of 0.3mL/min. The
injection volume was 10μL (full loop), and the sample man-
ager temperature was 10◦C. Mass spectrometry detection
was carried out using electrospray ionization operating at
positive mode. The main other instrumental settings were
capillary voltage 2KV; cone voltage 30V; extractor 1V;
ion energy1 1; Ion energy2 3; source temperature 120◦C;
desolvation temperature 300◦C; cone gas ﬂow rate 0L/h,
desolvation gas ﬂow rate 500L/h. Multiple reaction moni-
toring (MRM) was used to detect digoxin and metildigoxin,
with two transitions of ammonium adduct of each analyte,
one for quantitation and the other for conﬁrmation. The
appropriate MRM transitions, cone voltages and collisions
energies are described in Table 1.d 3-digoxin was used as
internal standard. Instrument control, data acquisition, and
process were achieved by the use of Waters MassLynx
software (Milford, Mass).
2.4. Sample Preparation and SPE Extraction. Control and
calibration samples were prepared by spiking drug-free
postmortem blood samples with standard solutions. OneInternational Journal of Analytical Chemistry 3
Table 1: MRM transitions, cone voltage and collision energy for
digoxin, metildigoxin, and d3-digoxin (IS).
Compound Transition Cone voltage
(V)
Collision
energy
Digoxin 798.5 > 651.53 0 1 6
798.5 > 781.53 0 8
Metildigoxin 812.6 > 651.53 0 1 5
812.6 > 795.63 0 9
d3-digoxin 801.5 > 654.63 0 1 5
milliliter of drug-free whole blood samples was ﬁrst spiked
with the substances at concentrations ranging from 0.3 to
10ng/mL. Deuterated internal standard (IS), d3-Digoxin,
was used by adding 50μL of a 100ng/mL solution to all the
samples examined. Five hundred microliters of ammonium
acetate 2M solution (pH = 9.5) and 3.5mL Mili-Q water
were added and ﬂowed by agitation on a vortex mixer. The
samples were then centrifuged for 15 minutes at 3200rpm
before extraction, and the supernatant decanted to another
tube. A solid-phase extraction (SPE) technique was carried
out to isolate the analytes, using Oasis HLB columns (3cc;
60mg). SPE columns were conditioned by sequentially
adding 1mL of methanol, 1mL of water, and 3mL of a
0.1M ammonium acetate solution (pH = 9.5). The prepared
samples were poured onto the conditioned columns and
allowed to drain. Each column was then washed with 2mL
of a 0.1M ammonium acetate solution (pH = 9.5) and
dried under maximum vacuum for 2min. The cardiac
glycosides were then eluted with 3mL of chloroform:2-
propanol (95:5). The solvent was evaporated to dryness at
25◦C under gentle nitrogen ﬂow. Residues were redissolved
with 100μL of acetonitrile/water (60:40) and vortexed to
increase recovery from tube walls. Ten microlitres of the ﬁnal
solution was then injected into the UPLC-MS/MS system.
3. Results andDiscussion
3.1. Method Development. There are various studies in the
literature reporting the development of methods for digoxin
determination in human plasma, serum, and urine by liquid
chromatography-mass spectrometry LC-MS [6–12], and
some describe the determination of digoxin in rat urine or
plasma [13, 14]. However, only few data have been published
about digoxin analysis in whole blood samples [15–17].
Furthermore, to the best of our knowledge, the present study
is the ﬁrst one to report a validated method for the analysis
of metildigoxin, the second more frequently used cardiac
glycoside in Portugal, in whole human blood. On the other
hand, only one publication reports the analysis of digoxin by
UPLC,butthestudywasperformedinraturine[13].Thus,it
isimportanttodevelopnewmethodsconcerningtheanalysis
of these digitalis glycosides in whole blood samples, the most
frequently analysed matrix in postmortem cases.
In the present study, a sensitive and rapid UPLC-MS/MS
methodforthedeterminationofdigoxinandmetildigoxinin
postmortembloodsampleswasdevelopedandvalidated,with
suﬃcient chromatographic separation (Figure 3) and precise
quantiﬁcation of the studied substances. Moreover, the use
of this new UPLC technique with tandem mass spectrometry
makesthedevelopedmethodasimpleandsuitabletechnique
for routine forensic analysis, with less time-consuming
analysis and more sensitivity and speciﬁcity.
Thus, validation studies were performed separately for
each substance, in whole blood samples. The chromato-
graphic method described had a run time of only 1.5min,
with digoxin detection at a retention time of 0.78 and
0.92min for metildigoxin (Figure 3). The ionization of the
studied cardiac glycosides by electrospray ionization (ESI) in
positive mode achieved the best results, since the positive
ion full-scan mass spectra of both compounds demonstrated
that the ammonium adduct ion in the positive mode showed
very strong intensity compared to the [M-H]− in the neg-
ative mode. Consequently, ammonium adduct of both
compounds was selected as the precursor ion. The product
ionswereobtainedbytheammoniumadductprecursorfrag-
mentationinacollisioncell.Thecompoundswerequantiﬁed
employing the MRM mode using the transitions 798.5 >
651.5 for digoxin and 812.6 > 651.5 for metildigoxin, and
the transitions for conﬁrmation, 798.5 > 781.5 for digoxin,
and 812.6 > 795.6 for metildigoxin (Table 1). Figures 4 and
5 represent the product ion mass spectra of digoxin and
metildigoxin, respectively.
3.2. Validation of the UPLC-MS/MS Method. The developed
method was validated according to the guidelines of the
International Conference on Harmonization (ICH) for the
validation of the following parameters: selectivity/speciﬁcity,
linearity,limitsofdetectionandquantiﬁcation,recovery,and
intra- and interday precision [18].
3.2.1. Speciﬁcity. To evaluate peak purity and selectivity, 10
diﬀerent blank samples (no analyte or internal standard was
added) were analyzed to check for peaks that might interfere
with the detection of the analyte or internal standard (IS).
Also, negative samples (blank blood samples + IS) were
analyzed, to verify the absence of native analyte in the IS
solution. In addition, ten blood samples spiked with the 2
analytes but without IS were analysed, in order to verify
no interferences from the analytes in the IS retention
time. To assess possible interferences, 10 diﬀerent samples
were spiked with a mixture of various benzodiazepines
(bromazepam, nordiazepam, 7-aminoﬂunitrazepam, ﬂuni-
trazepam, oxazepam, diazepam, clonazepam, temazepam
and midazolam) at a concentration of 25ng/mL and with
digoxin and metildigoxin at 5ng/mL. All 10 samples were
free of coeluting peaks at the retention times of the corre-
sponding studied substances and their respective deuterated
IS. Analysis of negative samples also demonstrated that
the IS did not contain relevant amounts of native cardiac
glycosides. None of the 10 compounds tested showed any
interference when added to a blood sample with 5ng/mL
digoxin and metildigoxin.
3.2.2. Limit of Detection (LOD) and Quantitation (LOQ).
The limit of detection (LOD) was estimated from extracted
samplesspiked withdecreasing concentrationsof thestudied4 International Journal of Analytical Chemistry
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Figure 3: MRM chromatograms of whole blood samples spiked with 1ng/mL of digoxin [(a) and (b)] and metildigoxin [(d) and (e)]; and
with 5ng/mL of d3-digoxin, internal standard (c).
compounds. The limits of detection (LOD) and quantitation
(LOQ) were established using the standard deviation of the
response (σ) and the slope of the linear regression (S), as
LOD =3.3σ/SandLOQ =10σ/S.Thistechniquealsoshowed
high sensitivity with a 0.09ng/mL LOD and a 0.28ng/mL
LOQ, for both substances, digoxin and metildigoxin.
3.2.3. Linearity. Simple linear regression analyses were per-
formed, with calibration curves constructed from peak
area ratios, spiking whole blood samples with the studied
substances at 10 diﬀerent concentrations of the cardiac gly-
cosidescoveringtherangeof(0.3–10)ng/mL.Tencalibrators
were used to generate the standard curve, each calibratorInternational Journal of Analytical Chemistry 5
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Figure 4: Product ion mass spectra of digoxin.
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Figure 5: Product ion mass spectra of metildigoxin.6 International Journal of Analytical Chemistry
Table 2: Recovery and precision for digoxin in spiked whole blood samples.
Concentration (ng/mL) Mean (ng/mL) Extraction recovery (%) CV (%)
Intraday Interday
11 .11 ±0.13 88 ±7 4.56–10.00 7.80
33 .27 ±0.23 83 ±2 1.95–7.35 4.83
87 .42 ±0.70 100 ±3 0.78–9.91 5.82
Table 3: Recovery and precision for metildigoxin in spiked whole blood samples.
Concentration (ng/mL) Mean (ng/mL) Extraction recovery (%) CV (%)
Intraday Interday
11 .21 ± 0.08 62 ±5 4.56–9.90 7.45
33 .23 ± 0.26 67 ±3 4.82–9.62 7.51
87 .96 ± 0.78 94 ±8 2.32–9.80 6.65
injected in three aliquots. Calibration curves showed a linear
relationshipfordigoxinwithacorrelationcoeﬃcientof0.994
and for metildigoxin with a correlation coeﬃcient of 0.996.
3.2.4. Precision. Intraday and interday coeﬃcients of varia-
tion values were determined by replicate analyses (n = 5)
of postmortem spiked blood aliquots, either on the same
run (intraday) or on ﬁve separate days (interday). Three
concentration levels were selected for validation (1, 3, and
8ng/mL).ThedataonprecisionarepresentedinTables2and
3. For digoxin and metildigoxin, good precision values were
obtained,shownbythelowpercentvaluesclearlybelow15%,
at the three concentration levels studied.
3.2.5. Extraction Recovery. The recovery of SPE was deter-
mined by repeated analysis of ﬁve samples spiked at three
diﬀerent levels of digoxin and metildigoxin concentration (1,
3, and 8ng/mL). The extraction recovery was determined by
comparing the representative peak areas of extracted drug-
free samples spiked before extraction with the peak area of
drug-free samples fortiﬁed after the extraction at the same
concentration levels. Tables 2 and 3 also show that the
calculated extraction eﬃciencies for digoxin ranged from
83 to 100% and from 62 to 94%, for metildigoxin. The
method provided good extraction eﬃciencies for digoxin at
all concentration levels. However, for metildigoxin, lower
(but still good) recoveries were achieved, especially in lower
concentrations. No signiﬁcant matrix eﬀect was observed for
the analytes in the analyzed samples. Sample preparation is
extremely important to the overall method with respect to
increasing the sensitivity and reducing possible interference
from the sample matrix. The extraction technique employed
allowedgoodrecoveryandappropriateselectivityandwas,at
the same time, simple and reproducible.
4. Conclusion
In summary, this paper describes an UPLC-MS/MS proce-
dure for quantitative analysis of digoxin and metildigoxin
in postmortem whole blood samples. The procedure pre-
sented here has high speciﬁcity, selectivity, and sensitivity
and very good limits of detection and quantiﬁcation and
can be regarded as an alternative method to detect and
quantify therapeutic levels of these cardiac glycosides [5, 19],
being less demanding and time consuming. In fact, this
methodology proved to be less laborious, overcoming some
disadvantages of the existing methodologies. The method
also proved to be selective and sensitive for a reduced sample
volume, despite the very low therapeutic levels, which is
a distinct advantage for the accomplishment of toxicological
analysis in forensic toxicology.
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